Most people diagnosed with multiple sclerosis live 25 to 35 years after diagnosis, even in historical studies that predate modern treatments. A large 60-year analysis found the median life expectancy for people with MS was 74.7 years, compared to 81.8 years in the general population. That translates to roughly 7 to 14 fewer years of life, though individual outcomes vary enormously depending on the type of MS, how quickly disability accumulates, and other health conditions.
These numbers draw heavily from eras when disease-modifying treatments either didn’t exist or were limited. The first approved therapy didn’t arrive until the mid-1990s, so decades of data reflect what MS looks like when it runs its natural course. That makes them directly relevant to the question of living without treatment.
What the Pre-Treatment Era Tells Us
Before disease-modifying therapies became available, researchers tracked large groups of MS patients for decades. These natural history studies show that MS, on its own, is rarely a rapidly fatal disease. Median survival from disease onset was about 40.6 years in one major long-term study, compared to 54.6 years for the matched general population. That gap has been narrowing over time. Survival from onset is now more than twice as long as what was reported in the first major study on the topic in 1969, reflecting improvements in general medical care, diagnostic tools, and overall quality of life, not just MS-specific drugs.
Without treatment, about one-third of people with MS need a wheelchair or mobility aid after 20 years. That means two-thirds do not. MS is extraordinarily variable. Some people experience a handful of relapses and accumulate little disability over decades. Others progress more quickly toward significant physical limitations. The trajectory you’re on in the first few years, particularly how fast disability builds early, is one of the strongest predictors of long-term outcomes.
Factors That Shorten or Lengthen Survival
Several factors consistently predict how MS affects lifespan, with or without treatment.
- Age at onset. People diagnosed later in life tend to have shorter survival times. Each additional year of age at diagnosis slightly increases mortality risk.
- Type of MS. Primary progressive MS, which involves steady worsening from the start rather than relapse-and-remission cycles, is associated with faster disability and higher mortality.
- Early disability accumulation. Reaching moderate disability milestones quickly (within the first several years) signals a more aggressive course.
- Socioeconomic status. Lower income and reduced access to supportive care are independently linked to worse outcomes.
Vascular health plays a surprisingly large role. Conditions like high blood pressure and diabetes speed up disability progression significantly. In one study of over 2,700 people with MS, both hypertension and diabetes were tied to reaching major disability milestones faster. Depression and cardiovascular disease are also consistently linked to increased mortality. Managing these conditions may matter nearly as much as treating MS itself.
How People With MS Actually Die
MS itself is rarely listed as the direct cause of death. Instead, the complications of advanced disability are what prove fatal. Infections, particularly respiratory infections, are the leading immediate cause, accounting for over half of deaths in one large Finnish study. When MS progresses to the point of significant immobility, the body becomes more vulnerable to pneumonia and other infections that a mobile person would fight off more easily.
Cardiovascular disease is a major contributor as well, especially after age 60. This partly reflects the sedentary lifestyle that advanced MS can impose and partly reflects the same vascular risk factors that affect the general population.
Suicide is a real and underrecognized risk. People with MS face roughly 1.7 times the suicide risk of the general population. That risk is highest around the time of diagnosis, when it rises to about twice the general population rate. The psychological weight of a new MS diagnosis, combined with uncertainty about the future, creates a particularly vulnerable window.
What “Without Treatment” Really Means Today
It’s worth distinguishing between two very different situations: choosing not to take disease-modifying therapy, and receiving no medical care at all. Most of the survival data we have reflects people who had access to doctors, physical therapy, treatment for relapses with steroids, and management of complications like infections and spasticity. They simply didn’t have the drugs that reduce relapse frequency and slow disease progression.
Modern disease-modifying therapies do appear to extend life and slow disability. The improvement in median survival over the past several decades likely reflects their impact alongside better diagnostics and general healthcare. But even without these specific drugs, people with MS lived for decades. The natural history data makes that clear.
If you’re considering whether to start or continue treatment, the key question isn’t whether MS is survivable without it. It is. The more relevant question is about quality of life and disability accumulation over time. Treatment primarily changes the speed at which disability progresses, which in turn affects independence, mobility, and the complications that ultimately shorten life. Someone with relapsing-remitting MS who stays physically active, manages vascular risk factors, and addresses mental health may do well for a very long time regardless of their treatment decisions. Someone with aggressive early disease and additional health problems faces a steeper trajectory.
Men vs. Women
As with the general population, women with MS tend to live longer than men. Median life expectancy for women with MS is about 77.2 years, compared to 72.2 years for men. Women are also more likely to have relapsing-remitting MS, which carries a better prognosis than progressive forms. Men are more likely to develop primary progressive MS and tend to accumulate disability faster, though there’s wide individual variation within both groups.